Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(6):406-409
DOI: 10.5428/pcar20180603
Research advances in relationship between proton pump inhibitors application and chronic kidney diseases
1. CHENG BingFeng(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China 884015615@qq.com)
2. CHEN Wei(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China )
3. GUO ZhiYong(Department of Nephrology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China drguozhiyong@163.com)
ABSTRACT  Proton pump inhibitors(PPI) are now widely used in clinical practice.This paper mainly discusses the relationship between PPI and chronic kidney diseases(CKD) from the perspective of clinical case studies and pathological mechanisms,and analyzes the risk of kidney injuries caused by PPI and the increasing risks of CKD,so as to provide reference for clinical safe medication.
Welcome to PCAR! You are the number 188 reader of this article!
Please cite this article as:
CHENG BingFeng,CHEN Wei,GUO ZhiYong,. Research advances in relationship between proton pump inhibitors application and chronic kidney diseases[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(6): 406-409.
References:
1. Nehra A K,Alexander J A,Loftus C G,et al.Proton pump inhibitors:review of emerging concerns[J].Mayo Clin Proc,2018,93(2):240-246.
2. LI TingTing,XIE Yan,Al-Aly Z.The association of proton pump inhibitors and chronic kidney disease:cause or confounding?[J].Curr Opin Nephrol Hypertens,2018,27(3):182-187.
3. Reeve E,Andrews J M,Wiese M D,et al.The feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors[J].Ann Pharmacother,2015,49(1):29-38.
4. YIN Gang,ZHANG ShiGe.Analysis of application trend and related problems of proton pump inhibitors in the national hospital system from 2010 to 2013[J].Eval Anal Drug-use Hosp China,2016,16(6):817-820.In Chinese with English abstract.
5. Cheungpasitporn W,Thongprayoon C,Kittanamongkolchai W,et al.Proton pump inhibitors linked to hypomagnesemia:a systematic review and meta-analysis of observational studies[J].Ren Fail,2015,37(7):1237-1241.
6. Lambert A A,Lam J O,Paik J J,et al.Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy:a systematic review and meta-analysis[J].PLoS One,2015,10(6):e0128004.
7. Gomm W,von Holt K,Thomé F,et al.Association of proton pump inhibitors with risk of dementia:a pharmacoepidemiological claims data analysis[J].JAMA Neurol,2016,73(4):410-416.
8. Zhou B,Huang Y,Li H,et al.Proton-pump inhibitors and risk of fractures:an update meta-analysis[J].Osteoporos Int,2016,27(1):339-347.
9. Tariq R,Singh S,Gupta A,et al.Association of gastric acid suppression with recurrent Clostridium difficile infection:a systematic review and meta-analysis[J].JAMA Intern Med,2017,177(6):784-791.
10. Sierra F,Suarez M,Rey M,et al.Systematic review:proton pump inhibitor-associated acute interstitial nephritis[J].Aliment Pharmacol Ther,2007,26(4):545-553.
11. Blank M L,Parkin L,Paul C,et al.A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use[J].Kidney Int,2014,86(4):837-844.
12. Klepser D G,Collier D S,Cochran G L.Proton pump inhibitors and acute kidney injury:a nested case-control study[J].BMC Nephrol,2013,14:150.
13. Antoniou T,Macdonald E M,Hollands S,et al.Proton pump inhibitors and the risk of acute kidney injury in older patients:a population-based cohort study[J].CMAJ Open,2015,3(2):E166-E171.
14. Lazarus B,CHEN Yuan,Wilson F P,et al.Proton pump inhibitor use and the risk of chronic kidney disease[J].JAMA Intern Med,2016,176(2):238-246.
15. XIE Yan,Bowe B,LI TingTing,et al.Proton pump inhibitors and risk of incident CKD and progression to ESRD[J].J Am Soc Nephrol,2016,27(10):3153-3163.
16. XIE Yan,Bowe B,LI TingTing,et al.Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury[J].Kidney Int,2017,91(6):1482-1494.
17. Peng Y C,LIN ChengLi,Yeh H Z,et al.Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases:a population-based,case control study[J].Medicine,2016,95(15):e3363.
18. Klatte D C F,Gasparini A,XU Hong,et al.Association between proton pump inhibitor use and risk of progression of chronic kidney disease[J].Gastroenterology,2017,153(3):702-710.
19. Hung S C,LIAO KuanFu,Hung H C,et al.Using proton pump inhibitors correlates with an increased risk of chronic kidney disease:a nationwide database-derived case-controlled study[J].Family Pract,2017,35(2):166-171.
20. Wijarnpreecha K,Thongprayoon C,Chesdachai S,et al.Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease:a meta-analysis[J].Dig Dis Sci,2017,62(10):2821-2827.
21. Schneeweiss S.Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics[J].Pharmacoepidemiol Drug Saf,2006,15(5):291-303.
22. Coca S G,Singanamala S,Parikh C R.Chronic kidney disease after acute kidney injury:a systematic review and meta-analysis[J].Kidney Int,2012,81(5):442-448.
23. Hrmark L,van der Wiel H E,de Groot M C,et al.Proton pump inhibitor-induced acute interstitial nephritis[J].Br J Clin Pharmacol,2007,64(6):819-823.
24. Park C H,Kim E H,Roh Y H,et al.The association between the use of proton pump inhibitors and the risk of hypomagnesemia:a systematic review and meta-analysis[J].PLoS One,2014,9(11):e112558.
25. Tin A,Grams M E,Maruthur N M,et al.Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease[J].Kidney Int,2015,87(4):820-827.
26. YU Lei,YU LiYuan,SUN LuNing,et al.Progress in renal adverse reactions caused by proton pump inhibitors[J].Chin Hosp Pharm J,2017,37(16):1649-1652.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口